Owning the disease and becoming the "health management partner" of choice goes well beyond just providing a pill or device for treatment. It requires a cohesive, integrated care approach to disease management from prevention to early interception, diagnosis to treatment sequences, and compliance to effectiveness. And in a financially-driven environment where outcomes-based reimbursement models are becoming commonplace and newly-empowered patient populations are demanding more of companies to support their health and well-being, innovation must focus on addressing unmet, under-addressed or hidden needs that extend beyond pharmacological.
Enter Signals Analytics, creators of the only cloud-based analytical intelligence platform that transforms the world's unconnected data into actionable insights to enhance therapeutic outcomes, optimize product portfolio health and propel patient-centered innovation. By utilizing our revolutionary Decision Science as a Service platform, life sciences innovators can discern the combination of diagnostics, treatments, technologies and services that that can satisfy the holistic requirements of the patient, assure adherence and result in better therapeutic effectiveness.
“Signals empowers us to quickly grow our portfolio through ongoing monitoring of our potential licensing partners, acquisition targets and technology alliances.”
– Global R&D Commercial Strategy Head at a Top 5 Consumer Healthcare Company
Signals Impact to Your Business
Discover Unmet Disease Prevention, Treatment and Management Needs of Patients and Providers
Uncover White Space and Opportunity Horizons for Digital "Beyond the Pill" Patient-Centric Services
Explore Competitor Movements in Response to Emerging Disease States, Treatment Sequences and Therapeutic Devleopments
Utilize Patient, Healthcare Provider, Payor, Regulator and Public Sentiment to Create "Whole Product" Therapies
Analyze Buy, Build or Partner Scenarios for Horizontal Integration and Quicker Time to Market
A Top 10 Global Life Sciences Company Grows
Its Product Portfolio and Optimizes R&D Costs
A top 10 global pharmaceutical company was actively engaging in buy, build or partner analysis to augment its late-stage pipeline and avoid the costs of developing a “beyond the pill” solution. Within 4 weeks, Signals Playbook identified, evaluated and ranked 30 potential M&A targets that fit the client’s business objectives.
The Signals Difference
Precision Intelligence That Matters Most to Your Enterprise
Real Time Signals Detection with Validated Source Data
Built By Industry Experts For Industry Experts
Rapid Business Impact and Value Right Out of the Box
Machine Learning Combined with Human Intelligence
The Latest From Signals
1325 Avenue of the Americas, 25th Floor
New York, NY 10019
(917) 470 9110
7 Giborei Israel St.
P.O.B 8374, Netanya 4250407, Israel
+972 73 718 1650